Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies Inc (NASDAQ: ACLS) delivers critical ion implantation systems and semiconductor manufacturing solutions to leading global chipmakers. This page provides investors and industry professionals with a centralized hub for official company announcements, operational updates, and strategic developments.
Access timely updates including earnings reports, product launches, technology partnerships, and service expansions. Our curated collection ensures you stay informed about ACLS's role in advanced logic, silicon carbide processing, and semiconductor equipment innovation.
Discover press releases covering operational milestones, customer collaborations, and advancements in process control technologies. All content is verified for accuracy and relevance to support informed analysis of ACLS's market position and industry contributions.
Bookmark this page for direct access to Axcelis Technologies' latest news. Check regularly for updates on equipment deployments, aftermarket service initiatives, and strategic developments shaping semiconductor manufacturing.
Axcelis Technologies (ACLS) has announced a significant expansion of its share repurchase program, with its Board of Directors approving an additional $100 million in share repurchase authorization. This increase brings the total outstanding repurchase authorization to $215 million.
The company plans to increase its quarterly share repurchase activity while maintaining a strong balance sheet. The repurchases may be executed through open market or privately negotiated transactions under SEC's Rule 10b-18, with the possibility of implementing Rule 10b5-1 trading plans. President and CEO Russell Low attributed this decision to the company's strong cash position and solid execution, expressing confidence in their long-term business fundamentals.
The program remains flexible, as Axcelis has no obligation to repurchase shares and may suspend or discontinue the program at any time, subject to market conditions and other factors.
Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has announced its participation in two major upcoming investor conferences.
The company will attend the Susquehanna Financial Group Fourteenth Annual Technology Conference at the Lotte New York Palace Hotel on February 27-28, 2025, where management will conduct one-on-one and small group meetings with investors on February 27th.
Additionally, Axcelis will participate in the Morgan Stanley Technology, Media & Telecom Conference at the Palace Hotel, San Francisco, from March 3-6, 2025, with management hosting investor meetings on March 4th. Interested investors can arrange meetings through respective conference representatives.
Axcelis Technologies (NASDAQ: ACLS) reported Q4 2024 financial results with revenue of $252.4 million and diluted EPS of $1.54. The company's full-year 2024 performance showed revenue of $1.02 billion, down from $1.13 billion in 2023. Systems revenue decreased to $782.6 million from $883.6 million in 2023.
Despite revenue decline, gross margin improved to 44.7% in 2024 from 43.5% in 2023. Net income for 2024 was $201 million with diluted EPS of $6.15, compared to $246.3 million and $7.43 EPS in 2023. For Q1 2025, Axcelis expects revenues of approximately $185 million and diluted EPS of $0.38.
Management anticipates a near-term cyclical digestion period as customers absorb mature node capacity investments, particularly in China. The company plans to focus on product innovation, cost management, and customer collaboration to position for future growth.
Axcelis Technologies (NASDAQ: ACLS) announced its participation in SEMICON Korea 2025, scheduled for February 19-21 at the COEX Center in Seoul. The company will showcase its Purion™ platform of ion implanters at Booth #D622.
The exhibition will feature the company's flagship Purion™ Platform, offering advanced ion implantation technology for various applications, and the Purion Power Series™, designed for power devices with multi-wafer size compatibility. Axcelis will also display new upgrade offerings, including innovative source technology and productivity packages.
CEO Russell Low emphasized Korea's importance as a market and highlighted the company's expanded operations through its recently opened Asia HUB Warehouse and Axcelis Asia Operations Center, enhancing their manufacturing, engineering, services, and logistics capabilities in the Asia Pacific region.
Axcelis Technologies (Nasdaq: ACLS) has been awarded the 2024 SK hynix CSO Safety and Health Award, recognizing their outstanding commitment to safety standards in semiconductor manufacturing. The award was presented by Kim Youngsik, Chief Production Officer of SK hynix, at the SK hynix SUPEX Center in Icheon, Korea.
The prestigious recognition is given to select suppliers who demonstrate excellence in four key areas:
- Compliance with Regulations
- Compliance with SK hynix policies
- Improvements in Company's EHS performance
- Reducing Overall Risks in the Semiconductor Supply Chain
Russell Low, Axcelis' President and CEO, acknowledged the honor as a testament to their dedication to customer collaboration, satisfaction, and commitment to environmental sustainability and safety. SK hynix's CPO Kim Youngsik praised Axcelis' exceptional commitment to health and safety as fundamental to achieving their priorities and serving customers.
Axcelis Technologies (Nasdaq: ACLS), a leading supplier of ion implantation solutions for the semiconductor industry, has announced it will release its fourth quarter and full year 2024 financial results after market close on Monday, February 10, 2025.
The company will host a conference call to discuss these results on Tuesday, February 11, 2025, at 8:30 a.m. ET. Investors can access the webcast through Axcelis' website investor section or register directly as participants. The webcast replay will be available for 30 days after the call.
Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has announced its participation in the 27th Annual Needham Growth Conference. The event will take place at the Lotte New York Palace Hotel from January 14-17, 2025.
The company will conduct a fireside chat on Tuesday, January 14th at 3:00 p.m. EST and will be available for one-on-one meetings. Investors and interested parties can access a live webcast of the presentation through the Investors' section of Axcelis' website or via the provided webcast link. The presentation recording will remain available for 90 days after the event.
Axcelis Technologies (Nasdaq: ACLS) will showcase its Purion™ and GSD Ovation™ Series of ion implanters at SEMICON Japan 2024, taking place December 11-13 at Tokyo Big Sight. The company will present its comprehensive product lineup, including the Purion Power Series™ for silicon and silicon carbide wafer processing, Purion H™ Series for high current operations, and other specialized implanter solutions. The event will feature a technical presentation on SiC Power Device Manufacturing Ion Implant Technology and a networking reception. Axcelis aims to expand its market share in Japan by providing advanced ion implant technology to local chipmakers.
Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has announced its participation in two upcoming investor conferences. The company will attend the 2024 Wells Fargo TMT Summit at the Terranea Resort in Rancho Palos Verdes on December 3-4, 2024, where management will conduct one-on-one investor meetings. Additionally, Axcelis will participate in the 13th Annual NYC Summit at Mastro's New York on December 17, 2024, hosting small group meetings. The NYC Summit is invitation-only, restricted to accredited investors and publishing research analysts.
Axcelis Technologies (NASDAQ: ACLS) reported Q3 2024 financial results with revenue of $256.6 million, slightly up from $256.5 million in Q2. Operating profit decreased to $46.9 million from $52.8 million, while net income fell to $48.6 million ($1.49 per diluted share) from $50.9 million ($1.55 per share). Gross margin declined to 42.9% from 43.8%. The company expects Q4 2024 revenues of approximately $245 million with EPS of $1.25. Additionally, Axcelis corrected historical backlog figures, with Q2 2024 backlog revised to $879 million from previously reported $994 million. Q3 2024 backlog stands at $758 million.
FAQ
What is the current stock price of Axcelis Tech Ord (ACLS)?
What is the market cap of Axcelis Tech Ord (ACLS)?
